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next 2 years with gradual integration of two 
disparate cultures, another approach could 
be to intensify and strengthen current col-
laborations through an NIAAA–NIDA 
Joint Task Force. The NIH Director could 
determine a specific percentage of resources 
from each institute to be committed for 
collaborative research agendas modeled on 
the same governance and operational struc-
tures currently used by the Neuroscience 
Blueprint and the Basic Behavioral Research 
Operations Network. In this way, a clearer 
road map could be developed that provides 
for due diligence and critical information 
gathering to understand the practical needs 
and challenges of developing an informed 
organizational approach. Predetermined 
milestones can be used to evaluate progress 
and adjust course as needed to ensure a viable 
plan that incorporates all relevant research.
Importantly, although there are com-
mon mechanisms mediating the reward-
ing effects of alcohol and other drugs, 
distinctions also exist. For example, there 
is considerable evidence that substances of 
abuse express their addictive potential, in 
part, through similar brain circuits, most 
notably the cortico-mesolimbic dopamine 
circuit (Johnson, 2010). Nevertheless, 
despite decades of research, the approach 
of direct antagonism of cortico-mesolim-
bic dopamine receptors has not yet yielded 
efficacious medicines to treat addiction. In 
fact, pharmacological differences between 
alcohol and other drugs might hold the key 
to successful medications development for 
these different disorders. Thus, rather than 
The decades-old debate about the optimum 
organizational structure of the National 
Institute on Alcohol Abuse and Alcoholism 
(NIAAA) and National Institute on Drug 
Abuse (NIDA) has reached a crescendo with 
the recent deliberations of the Scientific 
Management Review Board, which, despite 
the lack of a crisis, proposed a structural 
reorganization that would dissolve the two 
institutes and create a new institute for sub-
stance use, abuse, and addiction, in hope of 
new scientific and public health advances 
(Collins, 2010). For a new institute to suc-
ceed, a multitude of potential challenges 
need to be negotiated effectively.
Notably, new funds will be needed, even 
in the current difficult national economic 
climate, to coalesce the infrastructure of 
NIAAA and NIDA and incorporate addic-
tion-related research currently conducted 
by other National Institutes of Health (NIH) 
institutes. To succeed, the new institute 
would also require an enormous amount 
of cooperation from other institutes as the 
portfolios of research in the areas of alcohol, 
tobacco, and other drug abuse are transferred 
to it. Thus, in the near term, a structural reor-
ganization would be less efficient and more 
costly than the individual institutes are cur-
rently. Only with careful strategic planning 
would it be possible to increase efficiency and 
reduce costs over time.
If the process moves forward smoothly, 
Dr. Francis Collins, NIH Director, has pro-
posed launching the new entity by October 
2012. However, if reorganization is to be 
unveiled slowly and progressively over the 
focusing on a narrow conceptualization of 
the addiction circuitry, the new institute 
should seek diligently to understand how 
diverse and complex mechanisms contrib-
ute to abuse of alcohol and other substances.
Nutt et al. (2010) noted that in the 
United Kingdom, the overall harm to both 
the individual and others was greatest for 
alcohol. Alcohol is the addictive substance 
that is most commonly used by the United 
States population, with a prevalence of 
about 65.4% (Table 1; Grant et al., 2011). 
Addiction to alcohol is, however, far less 
common, as a proportion of its use, than 
addiction to many other drugs of abuse. 
Nonetheless, Rehm et al. (2009) found that 
the total economic cost of alcohol abuse in 
the United States in 1998 was nearly $235 
billion (adjusted to 2007 international dol-
lars). The harm to society attributed to alco-
hol consumption often results from alcohol 
use disorders that include the inappropriate 
use of alcohol in situations such as before 
driving or by underage drinkers, rather 
than addiction to alcohol. A 2010 fact sheet 
from the Centers for Disease Control and 
Prevention reports that during 2000–2004, 
annual health-related economic losses in 
the United States due to cigarette smoking 
were estimated at $193 billion ($96 billion 
in direct medical costs plus $97 billion in 
lost productivity). Data from the Office 
of National Drug Control Policy in 2002 
showed that the total economic impact in 
the United States of all illicit drugs com-
bined was about $200 billion, but 60% of 
that amount was related to incarceration. 
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Health should also be included within 
this new institute to address prevention 
and treatment of comorbid substance use 
disorder and mental illness, as well as some 
behavioral addictive disorders.
These deliberations have identified an 
opportunity to increase collaboration and 
broaden the thinking and vision of scientists 
to promote public health. If a new institute 
for substance use, abuse, and addiction is 
established, new leadership that is credible 
and respected by both the alcohol and drug 
addiction communities is needed to drive 
the new institute, inspire new vistas, build 
more intensive collaborations, and motivate 
staff to do what they have always done best 
– serve the public good. Otherwise, the path 
toward a structural reorganization of a new 
institute that meets some of the promise 
proposed for it, even with careful and stra-
tegic planning, could become a famished 
road (Okri, 1992) that simply consumes 
people and resources with no tangible gains. 
Success in this difficult task would be made 
easier and less costly by first implementing 
carefully placed building blocks of increas-
ing functional reorganization. Indeed, for 
the structural reorganization of a new insti-
tute to succeed, attention needs to be paid 
to the devil in the details.
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Hence, the new institute should focus on (1) 
alcohol use disorders, including alcoholism, 
(2) tobacco addiction, and (3) illicit drug 
 addictions as a group, in that order.
Careful thought is needed to determine 
the programmatic components of the new 
institute. Fragmentation or segregation of 
ongoing programs such as those involving 
fetal alcohol spectrum disorders, alcoholic 
liver disease, or prevention and treatment 
does not serve the public good and must 
be avoided. Tobacco research should be 
a major focus of a new institute and not 
the sole purview of the National Cancer 
Institute (NCI) or National Heart, Lung 
and Blood Institute (NHLBI) so that the 
prevention and treatment of tobacco 
addiction is not subsumed by the study of 
its general health consequences. Indeed, 
tobacco is, by far, the most addictive of 
all the drugs (Table 1), followed by heroin 
and crack cocaine (percentage of past-
year users with past-year dependence; 
Grant et al., 2011). It would certainly be 
unreasonable to expect scientists within 
NCI and NHLBI to be experts on addic-
tion, and for many, such specialist training 
would be lacking. Comorbid alcohol and 
drug addiction is at the interface of a col-
laborative scientific enterprise and, in the 
future, should receive appropriate fund-
ing and opportunities for development. 
Because of the strong interrelationship 
between alcohol and tobacco use, abuse, 
and addiction, a new institute would not 
be well grounded if it did not incorporate 
both. It is intriguing to consider whether 
parts of the National Institute of Mental 
Table 1 | Past-year liability for various types of substance dependence, based on 200 million United States adults ≥18 years of age (2001–2002).
 Prevalence (%)  Number of individuals Percentage of past-year Number of individuals 
 of past-year use with past-year use users with past-year dependence with past-year dependence
Alcohol 65.44 130,880,000 5.82 7,617,216
Tobacco 27.66 55,320,000 46.13 25,519,116
Sedatives 1.24 2,480,000 5.42 134,416
Tranquilizers 0.93 1,860,000 5.04 93,744
Painkillers 1.81 3,620,000 6.3 228,060
Stimulants 0.49 980,000 14.34 140,532
Marijuana 4.07 8,140,000 7.96 647,944
Cocaine/crack 0.56 1,120,000 23.91 267,792
Hallucinogens 0.57 1,140,000 2.67 30,438
Solvents/inhalants 0.11 220,000 1.04 2,288
Heroin 0.03 60,000 26.96 16,176
The data in this table are from Wave I of the National Epidemiologic Survey on Alcohol and Related Conditions (2001–2002; Grant et al., 2011).
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